Sunshine Biopharma Inc.
SBFM · XNASCIK 1402328fmd_0VXSFPJ5DJWCGQVYCBQDN1S9G0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 0 | 0 | 4 | 24 | 35 | 36 |
| Cost of revenue | – | 0 | 0 | 0 | 0 | 0 | 3 | 16 | 24 | 24 |
| Gross profit | – | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 11 | 12 |
| Research and development | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 |
| Operating income | (1) | (1) | (1) | (1) | (1) | (2) | (27) | (5) | (6) | (6) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (3) | (0) | (1) | (0) | (2) | (10) | 0 | 1 | 0 | 0 |
| Income before taxes | – | – | – | – | – | (12) | (27) | (4) | (5) | (6) |
| Income tax expense | – | – | – | – | 0 | 0 | 0 | 0 | (0) | 0 |
| Net income from continuing operations | – | – | (2) | (1) | (3) | (12) | (27) | (5) | (5) | (6) |
| Net income | (3) | (1) | (2) | (2) | (3) | (12) | (27) | (5) | (5) | (6) |
| Net income to common shareholders | (3) | (1) | (2) | (2) | (3) | (12) | – | – | (5) | (6) |